Lumora was founded in 2002 by Laurence Tisi and Professor Jim Murray, when it was spun-out from the Institute of Biotechnology at the University of Cambridge to exploit unique intellectual property and expertise in bioluminescence.
In 2004 Lumora raised seed investment from an EU business angel group and the University of Cambridge Challenge Fund, funding proof of concept work, filing of intellectual property and the development of initial prototypes. Tate & Lyle Ventures (TLV) invested in a Series A financing round in December 2006 and the Company moved to its own premises to begin full-time operations. The Company focused on developing BART® based tests for Salmonella and Listeria and in 2008 the tests were successfully trialled by a leading, independent food pathogen reference laboratory. In the same year the core BART® patent granted in EU & USA, and further new patent filings were made.
2008 saw the landmark signing of our first collaborative research partnership which brought in additional revenues and underpinned Lumora’s transformation into a commercial operation. Lumora now employs 13 people with a wide range of experience and operates from a dedicated, 6,100 sq ft facility in Ely, Cambridgeshire. The scientific team of nine includes four senior post-docs as well as IVD industry experienced process development staff. Capabilities include bioinformatics, primer design, test optimisation, test evaluation, protocol optimisation, reagent stabilisation and scale-up guidance. Lumora has microbiology experts in-house and facilities to deal with many common pathogens.
In 2011 Lumora completed a Series B fundraising round, lead by Catapult Venture Managers and bringing follow-on funding from TLV, to support the company's drive into clinical in vitro diagnostics.